REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement

6 Sep 2023 07:00

RNS Number : 4715L
Omega Diagnostics Group PLC
06 September 2023
 

Omega Diagnostics Group plc

('Omega' or the 'Company')

 

AGM Statement

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health and Nutrition products, will hold its Annual General Meeting (AGM) today at 11.00am at Poets House, St Mary's Street, Ely, CB7 4EY.

 

Ahead of the meeting, Simon Douglas, Chairman of the Company, will make the following statement:

 

"At the start of the new financial year we continue to work towards achieving our strategic objectives for our Health and Nutrition Business, maintaining our market leading position whilst targeting organic growth to gain momentum and create value for our shareholders.

 

Whilst we maintain a very strong order book, one of our leading products, the FoodPrint® test, had some production challenges towards the end of the year which resulted in a drop in production yields and, as a consequence, a backlog in the fulfilment of some orders. As announced with our results last month, we have embedded new working practices that are now generating significantly higher production yields that will allow us to successfully address the order backlog. We have established new preventative procedures and will continue to make further improvements. 

 

We remain well-funded to deliver against our strategic objectives. We have started our journey into the US market and we will continue to work closely with strategic partners to develop bespoke microbiome and nutrigenomic test reports. The recent successful launch of our new digital "app", MyHealthTracker, will support our strong position in the market and give us a direct connection with our customers.

 

We are implementing the final parts of the turnaround strategy outlined last year. A turnaround year where we established a clear focus, with new objectives. It has seen a significant shift in the business, and our proposed name change to Cambridge Nutritional Sciences PLC (LON: CNSL) builds on our CNSLab brand and better reflects our goal of promoting a personalised and functional approach to health and nutrition. We will continue to reshape and restructure the Company as we implement our new strategy.

 

Finally, as previously announced, the Board continues to vigorously pursue its substantial counterclaim for losses incurred towards the DHSC, as a direct result of its failure to licence the necessary intellectual property to permit the contract to move forward and their failure to notify the Group of their inability to do so in a timely manner.

 

We as a Board remain positive and believe we are well-positioned to re-focus the business and build an exciting profitable enterprise for everyone and look forward to updating our shareholders in November at the Company's half year results."

 

Contacts: 

 

Omega Diagnostics Group PLC

www.omegadx.com

Jag Grewal, Chief Executive Officer

via Walbrook PR

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash / Edward Whiley / George Dollemore (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus / Lianne Applegarth

Mob: 07980 541 893 / 07584 391 303

Sam Allen

Mob: 07502 558 258

 

 

About Omega Diagnostics Group PLC

Omega (AIM: ODX) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.

 

www.omegadx.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMSSEFMIEDSEEU
Date   Source Headline
22nd May 202012:30 pmRNSExercise of Options and TVR
15th May 202011:05 amRNSSecond Price Monitoring Extn
15th May 202011:00 amRNSPrice Monitoring Extension
13th May 20202:00 pmRNSPrice Monitoring Extension
7th May 20208:15 amRNSExercise of Options and TVR
6th May 202011:00 amRNSPrice Monitoring Extension
4th May 202011:00 amRNSExercise of Options and TVR
1st May 20202:30 pmRNSHolding(s) in Company
1st May 20202:05 pmRNSSecond Price Monitoring Extn
1st May 20202:00 pmRNSPrice Monitoring Extension
30th Apr 202012:00 pmRNSExercise of Options and TVR
29th Apr 20205:37 pmRNSHolding(s) in Company
29th Apr 20207:00 amRNSHolding(s) in Company
28th Apr 20205:43 pmRNSHolding(s) in Company
28th Apr 20207:00 amRNSVISITECT® CD4 Advanced Disease - supply agreement
27th Apr 20204:42 pmRNSSecond Price Monitoring Extn
27th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Apr 20209:06 amRNSSecond Price Monitoring Extn
27th Apr 20209:00 amRNSPrice Monitoring Extension
27th Apr 20207:00 amRNSCE-Mark of COVID-19 ELISA antibody test
24th Apr 202011:00 amRNSPrice Monitoring Extension
20th Apr 20202:05 pmRNSSecond Price Monitoring Extn
20th Apr 20202:00 pmRNSPrice Monitoring Extension
20th Apr 20201:24 pmRNSHolding(s) in Company
20th Apr 20201:23 pmRNSHolding(s) in Company
20th Apr 20207:00 amRNSHolding(s) in Company
20th Apr 20207:00 amRNSCOVID-19 MTA signed with Mologic Ltd
16th Apr 20205:40 pmRNSHolding(s) in Company
16th Apr 20207:00 amRNSHolding(s) in Company
14th Apr 20203:06 pmRNSHolding(s) in Company
9th Apr 20204:41 pmRNSSecond Price Monitoring Extn
9th Apr 20204:36 pmRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSCOVID-19 Consortium MOU
6th Apr 20209:30 amRNSVISITECT® CD4 Advanced Disease evaluation
6th Apr 20208:34 amRNSHolding(s) in Company
2nd Apr 20207:00 amRNSChinese Approval for Food Detective® test
2nd Apr 20207:00 amRNSTrading Update
24th Jan 20207:00 amRNSGrant of Options under Company EMI Plan
21st Jan 20203:24 pmRNSHolding(s) in Company
20th Jan 20207:00 amRNSExercise of Options and Total Voting Rights
17th Jan 202010:30 amRNSNigerian MOH approval for VISITECT CD4 350 test
8th Jan 202012:13 pmRNSHolding(s) in Company
16th Dec 20194:05 pmRNSDirector/PDMR Shareholding
9th Dec 20194:30 pmRNSHolding(s) in Company
2nd Dec 20199:00 amRNSGrant of Share Options
2nd Dec 20197:00 amRNSInterim Results
2nd Dec 20197:00 amRNSNigerian order for VISITECT® CD4
25th Nov 20197:00 amRNSUpdate on Allergy test menu
21st Nov 20197:00 amRNSInvestor results briefing
22nd Oct 201911:39 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.